Pure Global
NCT05694455

Micro and Macro Circulation in Sepsis

Clinical Utility of Longitudinal Measurement of Hemodynamic Incoherence and Endothelial
Denver Health and Hospital Authority·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
Starling SV- Passive Leg Raise
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Denver Health and Hospital Authority
Location
Denver, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2022
End date
Jun 30, 2023
Enrollment
150 participants
Primary outcome

Need for Renal Replacement Therapy

Summary

Purpose: To assess the prognostic role of Handheld Vital Microscopy (HVM) and evaluate levels
 of endothelial glycocalyx (eGC) breakdown in patients demonstrating Hemodynamic Incoherence
 (HI), to elucidate a mechanistic link between the eGC and HI in order to inform prognostic
 enrichment of future resuscitation trials. We will serially evaluate MiH and the perfused
 boundary region (PBR, an visual proxy for eGC thickness) using HVM, and a validated
 circulating biomarker of eGC integrity.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05694455
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05694455 through Pure Global AI's free database. This phase not specified trial is sponsored by Denver Health and Hospital Authority and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.